The US Food and Drug Administration (FDA) today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene.
The US Food and Drug Administration (FDA) today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
On October 5, the US Food and Drug Administration (FDA) approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
In the United States, an estimated 30 million individuals have an eating disorder. Associated with the highest mortality rate of all mental illnesses, eating disorders claim the lives of nearly 20% of those affected.
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015.
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
New York – June 26, 2014 – Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business.
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib).
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).
Page 8 of 19
Results 71 - 80 of 188
Results 71 - 80 of 188